Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
88 participants
INTERVENTIONAL
2024-12-09
2025-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Therefore, the aim of the current study is to provide reliable data on the short-term effect of rTMS for the prevention of migraine. The investigators will follow the Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition, with the exception of study duration, which will be limited to four weeks of baseline, three sessions of rTMS within a 10-day timeframe and 4 weeks of follow-up as our study aims to examine short-term efficacy.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Active group
This group receives rTMS treatment.
rTMS treatment
Brightmind.AI´s rTMS protocol is applied
Determination of motor hotspot and motor treshold
Determination of motor hotspot and motor treshold
Sham group
This group receives sham treatment.
Determination of motor hotspot and motor treshold
Determination of motor hotspot and motor treshold
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
rTMS treatment
Brightmind.AI´s rTMS protocol is applied
Determination of motor hotspot and motor treshold
Determination of motor hotspot and motor treshold
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Stated willingness to comply with all study procedures and availability for the duration of the study
* Male or female, aged 18-65
* Migraine without aura, migraine with aura or chronic migraine according to the diagnostic criteria of the third edition of the International Classification of Headache Disorders (ICHD-3) - Age of onset before 50 years of age
* At least 4 migraine days in each of three subsequent 4- week periods preceding the screening period. (Subsequently, the investigators use month synonymous for 4-week periods)
* At least 4 migraine days during one month of baseline prior to treatment.
* Ability to distinguish migraine headaches from other headache types (e.g., tension-type headaches)
* Willing to adhere to the rTMS regimen and able to monitor MD in Migraine diary
* No changes in medication usage/regime for three months before the start of treatment (incl. use of acute abortion / rescue medication). In case of Erenumab, Fremanezumab, Galcanezumab no changes in usage/regime for six months before the start of treatment. Every medication is reported and documented.
* No changes in medication usage/regime during the entire study period (i.e., keeping acute intervention protocol as previously handled for the past three months; not introducing new approaches in intervention/ prevention during this time period (such as anti-nausea drugs not previously taken)). Every medication is reported \& documented.
* Use of a single drug for migraine prophylaxis is permitted as long as the dosage has not been altered within 3 months of starting the study and the dosage must not be altered for the entire duration of the study.
* No other stimulation techniques.
* No change in acupuncture, relaxation training, biofeedback, behavioral therapy or other psychological or psychotherapeutic interventions for three months preceding the study and during the entire study period investigator.
* Ability to read and understand the written information (patient information, migraine diary, CRF and Adverse Events (AE) collecting form)
* Completed baseline headache diary with missing data on not more than 5 of 28 days.
Exclusion Criteria
* More than 26 headache days during baseline
* Pregnant persons
* Usage of Onabotulinumtoxin A for managing chronic migraines.
* Medication-overuse according to ICHD-3
* Presence of metals or implanted devices that can be in close proximity the of device (i.e., above the neckline) and can be adversely affected by magnetic fields including:
* Stents
* Implanted stimulators
* Implanted vagus nerve or brain implants incl. deep brain stimulators
* Implanted electrical devices
* Cochlear implants for hearing
* Any magnetic implants
* Bullet fragments
* Grenade fragments
* Presence of heart pacemakers, defibrillator, intracardiac lines or medication pumps
* Known severe adverse reactions in response to rTMS
* Patients diagnosed with bipolar disorder, substance use disorders or psychosis
* Patients with a known medical history, as well as a family history, of seizures.
* Patients experiencing chronic sleep deprivation
* Patients with structural CNS disorders such as a brain tumor, stroke, or traumatic brain injury.
* Patients with chronic tinnitus in the judgement of the investigator
* Patients with other disorders interfering with the study in the judgement of the investigator.
* Treatment with another investigational drug or other intervention until the end of the study
* Botulinum toxin-based infusions for cosmetic reasons at the forehead within a period of six months prior to study inclusion until the final visit.
* Other clinically relevant pain syndromes
* Depression or anxiety in the judgement of the investigator as assessed by means of BDI-II (score 20 or above) and DASS-21 (score 14 or above).
* Severe health risks in the judgement of the investigator. In particular this includes assessing the risk associated with a history of malignancy of any organ system (other than localized basal cell carcinoma of the skin or in situ cervical cancer), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medical University of Vienna
OTHER
Brightmind.AI
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christian Wöber, Prof., PhD
Role: PRINCIPAL_INVESTIGATOR
Medical University Vienna
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Univ.-Klinik für Neurologie, Medizinische Universität Wien
Vienna, Vienna, Austria
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Christian Wöber, Prof. PhD
Role: primary
Christian Wöber, Prof
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2145/2023
Identifier Type: -
Identifier Source: org_study_id